#Retatrutide #Obesity #WeightManagement #Diabetes #GLP1 #GIP #MetabolicHealth #Endocrinology #ClinicalResearch #HealthcareInnovation #Pharmacy To view or add a comment, sign in ' Eli Lilly and Company has announced positive topline results from two additional Phase III trials of retatrutide, its investigational first-in-class GIP/GLP-1/glucagon triple receptor agonist for obesity and related metabolic conditions
That pattern has already started with semaglutide and is expected for other GLP-1s.[7][17] 3
There are many harmful weight-related health conditions associated with obesity and excess weight, like heart disease and kidney disease, that can be improved as part of the weight loss effects of semaglutide
Common side effects include nausea, vomiting, diarrhea, constipation, and indigestion particularly when first starting the medication or adjusting dosages
Before starting Lipo-C, tell your healthcare provider if you have any other medical conditions, including if you: Have or have had problems with your liver or kidneys
Youll usually stay on this dose for at least 4 weeks before moving to 7.5 mg, depending on how you feel and your clinicians advice